ScripThe TIGIT class claimed its latest casualty as iTeos Therapeutics’ belrestotug failed to show sufficient benefit in trials of patients with non-small cell lung cancer (NSCLC) and head and neck cancer,
ScripBeiGene has received formal approval from its shareholders to change its name to BeOne Medicines and move its domicile from the Cayman Islands to Switzerland, with the transaction set to close later i
ScripResults from a Phase III study in China of Akeso and Summit Therapeutics’ ivonescimab in non-small cell lung cancer (NSCLC) are an encouraging sign for the PD-1/VEGF-targeting bispecific antibody’s pi
ScripAkeso has garnered a regulatory nod for penpulimab from the US Food and Drug Administration, making the agent the second PD-1 checkpoint inhibitor originating from a Chinese drug maker in the US marke